Expression data from the rituximab-resistant lymphoma cell lines and the parental cell lines

ABSTRACT: Rituximab, a monoclonal antibody against CD20, has achieved great success in the treatment of B cell lymphoma, but many patients have shown resistance to it and led to disease progression eventually. At present, the mechanism of resistance is still not clear, but we consider that it may involve the multiple genes and multiple signaling pathways. Therefore, our study aimed at searching differentially expressed genes of rituximab resistant cell lines (RRCL) by cDNA microarray, and exploring the resistant mechanism of RRCL by using the subsequent bioinformatics methods. In this study, we successfully identified seventy up-regulated genes and forty-two down-regulated genes in both two RRCL. We also isolated the MAPK signaling pathway, which was the significantly enriched pathway in resistant m

ORGANISM(S): Homo sapiens

SUBMITTER: Fang Pan 

PROVIDER: E-GEOD-60327 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress